Skip to main content
SpringerLink
Log in

Monoclonal Gammopathy of Undetermined Significance

  • Chapter
  • First Online:
Neoplastic Diseases of the Blood

Abstract

The term monoclonal gammopathy of undetermined significance (MGUS) denotes the presence of a monoclonal protein (M protein) in persons without evidence of multiple myeloma (MM), Waldenström’s macroglobulinemia (WM), AL amyloidosis (AL), or other related diseases. MGUS is characterized by a serum M-protein concentration of less than 3.0 g/dL; less than 10 % clonal plasma cells in the bone marrow; and the absence of end-organ damage (CRAB—hypercalcemia, renal insufficiency, anemia, and bone lesions) related to the plasma cell proliferative disorder [1–4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.

    Article  Google Scholar 

  2. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.

    Article  PubMed  CAS  Google Scholar 

  3. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;6:1121–7.

    Article  CAS  Google Scholar 

  4. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev. 2003;194:112–39.

    Article  PubMed  CAS  Google Scholar 

  5. Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960–1961;56:211–31.

    Google Scholar 

  6. Katzmann JA, Kyle RA. Immunochemical characterization of immunoglobulins in serum, urine, and cerebrospinal fluid. In: Detrick B, Hamilton R, Folds J, editors. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, DC: ASM Press; 2006. p. 88–100.

    Google Scholar 

  7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–44.

    PubMed  CAS  Google Scholar 

  8. Rajkumar SV, Kyle RA. Conventional therapy and approach to management. Best Pract Res Clin Haematol. 2005;18(4):585–601.

    Article  PubMed  Google Scholar 

  9. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.

    Article  PubMed  CAS  Google Scholar 

  10. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.

    Article  PubMed  CAS  Google Scholar 

  11. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22(10):1933–7.

    Article  PubMed  CAS  Google Scholar 

  12. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575–8.

    Article  PubMed  CAS  Google Scholar 

  13. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517.

    Article  PubMed  CAS  Google Scholar 

  14. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med. 1999;123(2):106–7.

    PubMed  CAS  Google Scholar 

  15. Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem. 1991;28(pt3):253–9.

    Google Scholar 

  16. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem. 2009;55(8):1523–9.

    Article  PubMed  CAS  Google Scholar 

  17. Hallen J. Frequency of “abnormal” serum globulins (M-Components) in the aged. Acta Med Scand. 1963;173(Fasc 6):737–44.

    Google Scholar 

  18. Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Med Scand. 1966;179(2):235–47.

    Article  PubMed  CAS  Google Scholar 

  19. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood. 1972;40(5):719–24.

    PubMed  CAS  Google Scholar 

  20. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35(1):63–8.

    Article  PubMed  CAS  Google Scholar 

  21. Vladutiu AO. Prevalence of M-proteins in serum of hospitalized patients. Physicians’ response to finding M-proteins in serum protein electrophoresis. Ann Clin Lab Sci. 1987;17(3):157–61.

    PubMed  CAS  Google Scholar 

  22. Malacrida V, DeFranscesco D, Banfi G, Porta FA, Riches PG. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol. 1987;40:793–7.

    Article  PubMed  CAS  Google Scholar 

  23. Sala P, Tonutti E, Giuliano M, Fuccaro V, Bramezza M. Laboratory screening of monoclonal gammopathies: incidence of serum monoclonal immunoglobulins during a five years survey in a general hospital. Boll Ist Sieroter Milan. 1989;68(3):224–7.

    PubMed  CAS  Google Scholar 

  24. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.

    Article  PubMed  CAS  Google Scholar 

  25. Dispenzieri A, Katzmann JA, Kyle R, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721–8.

    Article  PubMed  Google Scholar 

  26. Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med. 1987;82(1):39–45.

    Article  PubMed  CAS  Google Scholar 

  27. Aguzzi F, Bergami MR, Gasparro C, Bellotti V, Merlini G. Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol. 1992;48(4):192–5.

    Article  PubMed  CAS  Google Scholar 

  28. Schechter GP, Shoff N, Chan Cea. The frequency of monoclonal gammopathy of undetermined significance in Black and Caucasian veterans in a hospital population. In: Obrams GI, Potter M, editors. Epidemiology and biology of multiple myeloma. Berlin: Springer; 1991. p. 83.

    Google Scholar 

  29. Singh J, Dudley Jr AW, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med. 1990;116(6):785–9.

    PubMed  CAS  Google Scholar 

  30. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly [erratum appears in Am J Med 1998 Oct;105(4):362]. Am J Med. 1998;104(5):439–44.

    Article  PubMed  CAS  Google Scholar 

  31. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904–6.

    Article  PubMed  CAS  Google Scholar 

  32. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468–73.

    Article  PubMed  Google Scholar 

  33. Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly [erratum appears in J Am Geriatr Soc 1993 Jun;41(6):622]. J Am Geriatr Soc. 1993;41(1):11–4.

    PubMed  CAS  Google Scholar 

  34. Kurihara Y, Shiba K, Fukumura Y, Kobayashi I, Kamei S. Occurrence of serum M-protein species in Japanese patients older than 50 years based on relative mobility in cellulose acetate membrane electrophoresis. J Clin Lab Anal. 2000;14(2):64–9.

    Article  PubMed  CAS  Google Scholar 

  35. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007;82(12):1474–9.

    Article  PubMed  Google Scholar 

  36. Landgren O, Weiss B. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial group: support for genetic factors in pathogeneses. Leukemia. 2009;23:1691–7.

    Article  PubMed  CAS  Google Scholar 

  37. Hurez D, Youinou P, Gombert J, Preud’Homme JL. Survey of monoclonal gammopathy in western France: incidence and unexpected high frequency of IgM. Immunology. 1985;56(3):557–60.

    PubMed  CAS  Google Scholar 

  38. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114(4):785–90.

    Article  PubMed  CAS  Google Scholar 

  39. Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114(4):791–5.

    Article  PubMed  CAS  Google Scholar 

  40. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64(5):814–26.

    Article  PubMed  CAS  Google Scholar 

  41. Kyle RA. ‘Benign’ monoclonal gammopathy. A misnomer? JAMA. 1984;251(14):1849–54.

    Article  PubMed  CAS  Google Scholar 

  42. Kyle RA. “Benign” monoclonal gammopathy–after 20 to 35 years of follow-up. Mayo Clin Proc. 1993;68(1):26–36.

    PubMed  CAS  Google Scholar 

  43. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton 3rd LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later [see comment]. Mayo Clin Proc. 2004;79(7):859–66.

    Article  PubMed  Google Scholar 

  44. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance [see comment]. N Engl J Med. 2002;346(8):564–9.

    Article  PubMed  Google Scholar 

  45. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma [see comment]. Mayo Clin Proc. 2003;78(1):21–33.

    Article  PubMed  Google Scholar 

  46. Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand. 1986;219(5):519–22.

    Article  PubMed  CAS  Google Scholar 

  47. Paladini G, Fogher M, Mazzanti G, et al. Idiopathic monoclonal gammopathy. Long-term study of 313 cases. Recenti Prog Med. 1989;80(3):123–32.

    PubMed  CAS  Google Scholar 

  48. Giraldo MP, Rubio-Felix D, Perella M, Gracia JA, Bergua JM, Giralt M. Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases. Sangre (Barc). 1991;36(5):377–82.

    CAS  Google Scholar 

  49. Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992;81(3):391–4.

    Article  PubMed  CAS  Google Scholar 

  50. Ucci G, Riccardi A, Luoni R, Ascari E. Presenting features of monoclonal gammopathies: an analysis of 684 newly diagnosed cases. Cooperative Group for the Study and Treatment of Multiple Myeloma. J Intern Med. 1993;234(2):165–73.

    Article  PubMed  CAS  Google Scholar 

  51. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol. 1995;91(1):121–5.

    Article  PubMed  Google Scholar 

  52. Isaksson E, Bjorkholm M, Holm G, et al. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br J Haematol. 1996;92(1):71–6.

    Article  PubMed  CAS  Google Scholar 

  53. Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87(3):912–8.

    PubMed  CAS  Google Scholar 

  54. Pasqualetti P, Festuccia V, Collacciani A, Casale R. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematol. 1997;97(3):174–9.

    Article  PubMed  CAS  Google Scholar 

  55. Carrell RW, Colls BM, Murray JT. The significance of monoclonal gammopathy in a normal population. Aust NZ J Med. 1971;1(4):398–401.

    Article  CAS  Google Scholar 

  56. Colls BM. Monoclonal gammopathy of undetermined significance (MGUS)-31 year follow up of a community study. Aust NZ J Med. 1999;29(4):500–4.

    Article  CAS  Google Scholar 

  57. Rosinol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82(4):428–34.

    Article  PubMed  CAS  Google Scholar 

  58. Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, Sorensen H. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 2001;112(2):353–7.

    Article  PubMed  CAS  Google Scholar 

  59. Gregersen H, Mellemkjaer L, Salling Ibsen J, et al. Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol. 2000;63(1):1–6.

    Article  PubMed  CAS  Google Scholar 

  60. Ogmundsdottir HM, Haraldsdottir V, Johannesson MG, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol. 2002;118(1):166–73.

    Article  PubMed  Google Scholar 

  61. Schaar CG, le Cessie S, Snijder S, et al. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol. 2009;144(2):176–84.

    Article  PubMed  Google Scholar 

  62. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–7.

    Article  PubMed  CAS  Google Scholar 

  63. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–22.

    Article  PubMed  CAS  Google Scholar 

  64. Kyle RA, Lust JA. The monoclonal gammopathies (paraproteins). Adv Clin Chem. 1990;28:145–218.

    Article  PubMed  CAS  Google Scholar 

  65. Kristinsson SY, Bjorkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance (MGUS): a population-based study. Haematologica. 2009;94:1714.

    Article  PubMed  Google Scholar 

  66. Iwanaga M, Tagawa M, Tsukasaki K, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood. 2009;113(8):1639–50.

    Article  PubMed  CAS  Google Scholar 

  67. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386–91.

    Article  PubMed  CAS  Google Scholar 

  68. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58(24):5640–5.

    PubMed  CAS  Google Scholar 

  69. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100(4):1417–24.

    PubMed  CAS  Google Scholar 

  70. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106(6):2156–61.

    Article  PubMed  CAS  Google Scholar 

  71. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59(18):4546–50.

    PubMed  CAS  Google Scholar 

  72. Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood. 1999;94(8):2583–9.

    PubMed  CAS  Google Scholar 

  73. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105(1):317–23.

    Article  PubMed  CAS  Google Scholar 

  74. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503–8.

    Article  PubMed  CAS  Google Scholar 

  75. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210–6.

    PubMed  Google Scholar 

  76. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064–73.

    PubMed  CAS  Google Scholar 

  77. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104(4):1159–65.

    Article  PubMed  CAS  Google Scholar 

  78. Melton 3rd LJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res. 2004;19(1):25–30.

    Article  PubMed  Google Scholar 

  79. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98(13):3534–40.

    Article  PubMed  CAS  Google Scholar 

  80. Lust JA, Donovan KA. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control. 1998;5(3):209–17.

    PubMed  Google Scholar 

  81. Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002;97(6):1371–4.

    Article  PubMed  Google Scholar 

  82. Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol. 2002;119(3):706–8.

    Article  PubMed  Google Scholar 

  83. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20(6):1625–34.

    Article  PubMed  Google Scholar 

  84. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–7.

    Article  PubMed  CAS  Google Scholar 

  85. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92.

    Article  PubMed  CAS  Google Scholar 

  86. Perez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2009;148(1):110–4.

    Article  PubMed  Google Scholar 

  87. Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123(4):631–6.

    Article  PubMed  CAS  Google Scholar 

  88. Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009;27(25):4197–203.

    Article  PubMed  CAS  Google Scholar 

  89. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347–9.

    Article  PubMed  CAS  Google Scholar 

  90. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–90.

    Article  PubMed  CAS  Google Scholar 

  91. Peltonen S, Wasastjerna C, Wager O. Clinical features of patients with a serum M component. Acta Med Scand. 1978;203(4):257–63.

    PubMed  CAS  Google Scholar 

  92. Dammacco F, Waldenstrom J. Bence Jones proteinuria in benign monoclonal gammapathies. Incidence and characteristics. Acta Med Scand. 1968;184(5):403–9.

    PubMed  CAS  Google Scholar 

  93. Lindstrom FD, Dahlstrom U. Multiple myeloma or benign monoclonal gammopathy? A study of differential diagnostic criteria in 44 cases. Clin Immunol Immunopathol. 1978;10(2):168–74.

    Article  PubMed  CAS  Google Scholar 

  94. Kyle RA, Maldonado JE, Bayrd ED. Idiopathic Bence Jones ­proteinuria–a distinct entity? Am J Med. 1973;55(2):222–6.

    Article  PubMed  CAS  Google Scholar 

  95. Bernier GM, Graham Jr RC. Plasma cell asynchrony in myeloma: correlation of light and electron microscopy. Semin Hematol. 1976;13(3):239–45.

    PubMed  CAS  Google Scholar 

  96. Greipp PR, Kyle RA. Clinical, morphological, and cell kinetic ­differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood. 1983;62(1):166–71.

    PubMed  CAS  Google Scholar 

  97. Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am. 1992;6(2):285–95.

    PubMed  CAS  Google Scholar 

  98. Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987;62(11):969–77.

    PubMed  CAS  Google Scholar 

  99. Witzig TE, Kyle RA, O’Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol. 1994;87(2):266–72.

    Article  PubMed  CAS  Google Scholar 

  100. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668–74.

    Article  PubMed  Google Scholar 

  101. Bellaiche L, Laredo JD, Liote F, et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. The GRI Study Group. Spine. 1997;22(21):2551–7.

    Article  PubMed  CAS  Google Scholar 

  102. Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L. Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol. 1997;58(2):104–8.

    Article  PubMed  CAS  Google Scholar 

  103. Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995;90(3):693–6.

    Article  PubMed  CAS  Google Scholar 

  104. Fonseca R, Ahmann GJ, Jalal SM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998;103(3):704–10.

    Article  PubMed  CAS  Google Scholar 

  105. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 1999;93(1):300–5.

    PubMed  CAS  Google Scholar 

  106. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276–9.

    Article  PubMed  CAS  Google Scholar 

  107. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231–9.

    Article  PubMed  CAS  Google Scholar 

  108. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147(1):22–42.

    Article  PubMed  CAS  Google Scholar 

  109. Dexter RN, Mullinax F, Estep HL, Williams Jr RC. Monoclonal IgG gammopathy and hyperparathyroidism. Ann Intern Med. 1972;77(5):759–64.

    PubMed  CAS  Google Scholar 

  110. Schnur MJ, Appel GB, Bilezikian JP. Primary hyperparathyroidism and benign monoclonal gammopathy. Arch Intern Med. 1977;137(9):1201–3.

    Article  PubMed  CAS  Google Scholar 

  111. Mundis RJ, Kyle RA. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1982;77(5):619–21.

    PubMed  CAS  Google Scholar 

  112. Rao DS, Antonelli R, Kane KR, Kuhn JE, Hetnal C. Primary hyperparathyroidism and monoclonal gammopathy. Henry Ford Hosp Med J. 1991;39(1):41–4.

    PubMed  CAS  Google Scholar 

  113. Migliore PJ, Alexanian R. Monoclonal gammopathy in human neoplasia. Cancer. 1968;21(6):1127–31.

    Article  PubMed  CAS  Google Scholar 

  114. Talerman A, Haije WG. The frequency of M-components in sera of patients with solid malignant neoplasms. Br J Cancer. 1973;27(4):276–82.

    Article  PubMed  CAS  Google Scholar 

  115. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84(8):685–93.

    Article  PubMed  Google Scholar 

  116. Azar HA, Hill WT, Osserman EF. Malignant lymphoma and lymphatic leukemia associated with myeloma-type serum proteins. Am J Med. 1957;23(2):239–49.

    Article  PubMed  CAS  Google Scholar 

  117. Kyle RA, Bayrd ED, McKenzie BF, Heck FJ. Diagnostic Criteria for electrophoretic patterns of serum and urinary proteins in multiple myeloma: study of one hundred and sixty-five multiple myeloma patients with similar electrophoretic patterns. JAMA. 1960;174:245–51.

    Article  PubMed  CAS  Google Scholar 

  118. Krauss S, Sokal J. Paraproteinemia in the lymphomas. Am J Med. 1966;40:400.

    Article  Google Scholar 

  119. Hallen J. M-components in leukaemia, in lymphosarcoma and in reticulum cell sarcoma. Acta Med Scand. 1966;462:71.

    Google Scholar 

  120. Kim H, Heller P, Rappaport H. Monoclonal gammopathies associated with lymphoproliferative disorders: a morphologic study. Am J Clin Pathol. 1973;59:582.

    Google Scholar 

  121. Moore DF, Migliore PJ, Shullenberger CC, Alexanian R. Monoclonal macroglobulinemia in malignant lymphoma. Ann Intern Med. 1970;72(1):43–7.

    PubMed  CAS  Google Scholar 

  122. Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med. 1975;135(1):62–6.

    Article  PubMed  CAS  Google Scholar 

  123. Hobbs J, Carter P, Cooke KB, et al. IgM paraproteins. J Clin Pathol. 1974;28:54.

    Google Scholar 

  124. Bain GO, Belch A. Nodular mixed cell lymphoma with monoclonal gammopathy. Am J Clin Pathol. 1981;76(6):832–7.

    PubMed  CAS  Google Scholar 

  125. Pangalis GA, Nathwani BN, Rappaport H. Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenstrom. Cancer. 1977;39(3):999–1010.

    Article  PubMed  CAS  Google Scholar 

  126. Ko HS, Pruzanski W. M components associated with lymphoma: a review of 62 cases. Am J Med Sci. 1976;272(2):175–83.

    Article  PubMed  CAS  Google Scholar 

  127. Ng JP, Jones EL, Pati A, Strevens MJ, Guha T. Hodgkin’s disease and paraproteinaemia: a case report and review of the literature. Clin Lab Haematol. 1992;14(3):257–61.

    PubMed  CAS  Google Scholar 

  128. Magrath I, Benjamin D, Papadopoulos N. Serum monoclonal immunoglobulin bands in undifferentiated lymphomas of Burkitt and non-Burkitt types. Blood. 1983;61(4):726–31.

    PubMed  CAS  Google Scholar 

  129. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc. 1987;62(8):719–31.

    PubMed  CAS  Google Scholar 

  130. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123(2):200–5.

    Article  PubMed  Google Scholar 

  131. Asatiani E, Cohen P, Ozdemirli M, Kessler CM, Mavromatis B, Cheson BD. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol. 2004;77(2):144–6.

    Article  PubMed  Google Scholar 

  132. Schauer PK, Straus DJ, Bagley Jr CM, et al. Angioimmunoblastic lymphadenopathy: clinical spectrum of disease. Cancer. 1981;48(11):2493–8.

    Article  PubMed  CAS  Google Scholar 

  133. Offit K, Macris NT, Finkbeiner JA. Monoclonal hypergammaglobulinemia without malignant transformation in angioimmunoblastic lymphadenopathy with dysproteinemia. Am J Med. 1986;80(2):292–4.

    Article  PubMed  CAS  Google Scholar 

  134. Steinberg A, Seldin M, Jaffe E. Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med. 1988;108:575.

    PubMed  CAS  Google Scholar 

  135. Hineman VL, Phyliky RL, Banks PM. Angiofollicular lymph node hyperplasia and peripheral neuropathy: association with monoclonal gammopathy. Mayo Clin Proc. 1982;57(6):379–82.

    PubMed  CAS  Google Scholar 

  136. Sugai S, Konda S, Shirasaki Y. Non-IgM monoclonal gammopathy in patients with Sjogren’s syndrome. Am J Med. 1980;68:861.

    Article  PubMed  CAS  Google Scholar 

  137. Humphrey D, Cortes E, Spiva D. Immunohistologic studies of cytoplasmic immunoglobulins in rheumatic diseases including two patients with monoclonal patterns and subsequent lymphoma. Cancer. 1982;49:2049.

    Article  PubMed  CAS  Google Scholar 

  138. Ben-Chetrit E, Ben-Amitai D, Levo Y. The association between Kaposi’s sarcoma and dysgammaglobulinemia. Cancer. 1982;49(8):1649–51.

    Article  PubMed  CAS  Google Scholar 

  139. Kyle R, Bayrd E. The monoclonal gammopathies: multiple myeloma and related plasma-cell disorders. Springfield, IL: Charles C. Thomas; 1976. p. 415.

    Google Scholar 

  140. Noel P, Kyle RA. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol. 1987;87(3):385–8.

    PubMed  CAS  Google Scholar 

  141. Sinclair D, Sheehan T, Parrott DM, Stott DI. The incidence of monoclonal gammopathy in a population over 45 years old determined by isoelectric focusing. Br J Haematol. 1986;64(4):745–50.

    Article  PubMed  CAS  Google Scholar 

  142. Jansen J, Bolhuis RL, van Nieuwkoop JA, Schuit HR, Kroese WF. Paraproteinaemia plus osteolytic lesions in typical hairy-cell leukaemia. Br J Haematol. 1983;54(4):531–41.

    Article  PubMed  CAS  Google Scholar 

  143. Matsuzaki H, Yamaguchi K, Kagimoto T, Nakai R, Takatsuki K, Oyama W. Monoclonal gammopathies in adult T-cell leukemia. Cancer. 1985;56(6):1380–3.

    Article  PubMed  CAS  Google Scholar 

  144. Guglielmi P, Davi F, Brouet JC. Prevalence of monoclonal Ig with lambda light chains in chronic myelocytic leukaemia. Br J Haematol. 1989;73(3):331–3.

    Article  PubMed  CAS  Google Scholar 

  145. Buonanno G, Pandolfi F, Valente A, Napolitano M, Cafaro A, Gonnella F. Monocytic blast cell crisis and IgG-lambda monoclonal gammopathy in a Ph1  +  chronic myelogenous leukemia. Report of a case. Haematologica. 1986;71(6):489–92.

    PubMed  CAS  Google Scholar 

  146. Atkins H, Drouin J, Izaguirre CA, Sengar DS. Acute promyelocytic leukemia associated with a paraprotein that reacts with leukemic cells. Cancer. 1989;63(9):1750–1.

    Article  PubMed  CAS  Google Scholar 

  147. Van Camp B, Reynaerts P, Naets JP, Radl J. Transient IgA-lambda paraproteinemia during treatment of acute myelomonoblastic leukemia. Blood. 1980;55(1):21–5.

    PubMed  Google Scholar 

  148. Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournie B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand’s syndrome. Seven new cases with a literature review. Joint, Bone, Spine. Revue du Rhumatisme. 2002;69(1):62–7.

    Article  CAS  Google Scholar 

  149. Bellotti V, Gamba G, Merlini G, et al. Study of three patients with monoclonal gammopathies and ‘lupus-like’ anticoagulants. Br J Haematol. 1989;73(2):221–7.

    Article  PubMed  CAS  Google Scholar 

  150. Stern JJ, Ng RH, Triplett DA, McIntyre JA. Incidence of antiphospholipid antibodies in patients with monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1994;101(4):471–4.

    PubMed  CAS  Google Scholar 

  151. Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15(10):1490–4.

    Article  PubMed  CAS  Google Scholar 

  152. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–6.

    Article  PubMed  CAS  Google Scholar 

  153. Selroos O, von Knorring J. Immunoglobulins in pernicious anaemia. Including a report on a patient with pernicious anaemia, IgA deficiency and an M component of kappa-type IgG. Acta Med Scand. 1973;194(6):571–4.

    Article  PubMed  CAS  Google Scholar 

  154. Sandstrom H, Wahlin A, Eriksson M, Bergstrom I, Wickramasinghe SN. Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anaemia, type III. Eur J Haematol. 1994;52(1):42–6.

    Article  PubMed  CAS  Google Scholar 

  155. Resegotti L, Dolci C, Palestro G, Peschle C. Paraproteinemic variety of pure red cell aplasia: immunological studies in 1 patient. Acta Haematol. 1978;60(4):227–32.

    Article  PubMed  CAS  Google Scholar 

  156. Balducci L, Hardy C, Dreiling B, Tavassoli M, Steinberg MH. Pure red blood cell aplasia associated with paraproteinemia: in vitro studies of erythropoiesis. Haematologia (Budap). 1984;17(3):353–7.

    CAS  Google Scholar 

  157. Berner Y, Berrebi A. Myeloproliferative disorders and nonmyelomatous paraprotein. A study of five patients and review of the literature. Isr J Med Sci. 1986;22(2):109–12.

    PubMed  CAS  Google Scholar 

  158. Duhrsen U, Uppenkamp M, Meusers P, Konig E, Brittinger G. Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias. Blut. 1988;56(3):97–102.

    Article  PubMed  CAS  Google Scholar 

  159. Economopoulos T, Economidou J, Giannopoulos G, et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol. 1985;38(8):908–11.

    Article  PubMed  CAS  Google Scholar 

  160. Pratt PW, Kochwa S, Estren S. Immunoglobulin abnormalities in Gaucher’s disease. Report of 16 cases. Blood. 1968;31(5):633–40.

    PubMed  CAS  Google Scholar 

  161. Marti GE, Ryan ET, Papadopoulos NM, et al. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol. 1988;29(4):189–94.

    Article  PubMed  CAS  Google Scholar 

  162. Airo R, Gabusi G, Guindani M. Gaucher’s disease associated with monoclonal gammapathy of undetermined significance: a case report. Haematologica. 1993;78(2):129–31.

    PubMed  CAS  Google Scholar 

  163. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105(12):4569–72.

    Article  PubMed  CAS  Google Scholar 

  164. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005;34(3):197–200.

    Article  PubMed  Google Scholar 

  165. Zawadzki ZA, Benedek TG. Rheumatoid arthritis, dysproteinemic arthropathy, and paraproteinemia. Arthritis Rheum. 1969;12(6):555–68.

    Article  PubMed  CAS  Google Scholar 

  166. Hurst NP, Smith W, Henderson DR. IgG (kappa) paraproteinaemia and arthritis. Br J Rheumatol. 1987;26(2):142–6.

    Article  PubMed  CAS  Google Scholar 

  167. Michaux JL, Heremans JF. Thirty cases of monoclonal immunoglobulin disorders other than myeloma or macroglobulinemia. A classification of diseases associated with the production of monoclonal-type immunoglobulins. Am J Med. 1969;46(4):562–79.

    Article  PubMed  CAS  Google Scholar 

  168. Porcel JM, Ordi J, Tolosa C, Selva A, Castro-Salomo A, Vilardell M. Monoclonal gammopathy in systemic lupus erythematosus. Lupus. 1992;1(4):263–4.

    Article  PubMed  CAS  Google Scholar 

  169. Ali YM, Urowitz MB, Ibanez D, Gladman DD. Monoclonal gammopathy in systemic lupus erythematosus. Lupus. 2007;16(6):426–9.

    Article  PubMed  CAS  Google Scholar 

  170. Renier G, Renier JC, Gardembas-Pain M, Chevailler A, Boasson M, Hurez D. Ankylosing spondylitis and monoclonal gammopathies. Ann Rheum Dis. 1992;51(8):951–4.

    Article  PubMed  CAS  Google Scholar 

  171. Ilfeld D, Barzilay J, Vana D, Ben-Bassat M, Joshua H, Pick I. IgG monoclonal gammopathy in four patients with polymyalgia rheumatica. Ann Rheum Dis. 1985;44(7):501.

    Article  PubMed  CAS  Google Scholar 

  172. Kalra L, Delamere JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Br J Rheumatol. 1987;26(6):458–9.

    Article  PubMed  CAS  Google Scholar 

  173. Kiprov DD, Miller RG. Polymyositis associated with monoclonal gammopathy. Lancet. 1984;2(8413):1183–6.

    Article  PubMed  CAS  Google Scholar 

  174. Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997;41(1):100–4.

    Article  PubMed  CAS  Google Scholar 

  175. Nakayama T, Horiuchi E, Watanabe T, Murayama S, Nakase H. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption. J Neurol Neurosurg Psychiatry. 2000;68(2):230–3.

    Article  PubMed  CAS  Google Scholar 

  176. Powell FC, Greipp PR, Su WP. Discoid lupus erythematosus and monoclonal gammopathy. Br J Dermatol. 1983;109(3):355–60.

    Article  PubMed  CAS  Google Scholar 

  177. Freestone S, Ramsay LE. Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus. Br Med J (Clin Res Ed). 1982;285(6354):1536–7.

    Article  CAS  Google Scholar 

  178. Nakanishi H, Takehara K, Soma Y, Ishibashi Y. Atypical scleroderma associated with multiple myeloma. Dermatologica. 1989;178(3):176–8.

    Article  PubMed  CAS  Google Scholar 

  179. Scherf I, Nahir M, Brick R, Joffe G, Tatarsky J. Monoclonal IgG immunoglobulinemia in psoriatic arthritis. Dermatologica. 1980;160(5):348–50.

    Article  PubMed  CAS  Google Scholar 

  180. Kelly Jr JJ, Kyle RA, Miles JM, O’Brien PC, Dyck PJ. The spectrum of peripheral neuropathy in myeloma. Neurology. 1981;31(1):24–31.

    Article  PubMed  Google Scholar 

  181. Kahn SN, Riches PG, Kohn J. Paraproteinaemia in neurological disease: incidence, associations, and classification of monoclonal immunoglobulins. J Clin Pathol. 1980;33(7):617–21.

    Article  PubMed  CAS  Google Scholar 

  182. Johansen P, Leegaard OF. Peripheral neuropathy and paraproteinemia: an immunohistochemical and serologic study. Clin Neuropathol. 1985;4(3):99–104.

    PubMed  CAS  Google Scholar 

  183. Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci. 1993;114(2):193–9.

    Article  PubMed  CAS  Google Scholar 

  184. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383–90.

    Article  PubMed  CAS  Google Scholar 

  185. Baldini L, Nobile-Orazio E, Guffanti A, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom’s macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45(1):25–31.

    Article  PubMed  CAS  Google Scholar 

  186. Nobile-Orazio E, Francomano E, Daverio R, et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol. 1989;26(4):543–50.

    Article  PubMed  CAS  Google Scholar 

  187. Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann NY Acad Sci. 1971;190:507–18.

    Article  PubMed  CAS  Google Scholar 

  188. Kelly JJ, Kyle RA, Latov N. Polyneuropathies associated with plasma cell dyscrasias. Boston: Martinus Nijhoff; 1987.

    Book  Google Scholar 

  189. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995;37(Suppl 1):S32–42.

    Google Scholar 

  190. Kissel JT, Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromuscul Disord. 1996;6(1):3–18.

    Article  PubMed  CAS  Google Scholar 

  191. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. [Review]. N Engl J Med. 1998;338(22):1601–7.

    Article  PubMed  CAS  Google Scholar 

  192. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988;3(4):301–32.

    PubMed  CAS  Google Scholar 

  193. Hafler DA, Johnson D, Kelly JJ, Panitch H, Kyle R, Weiner HL. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics. Neurology. 1986;36(1):75–8.

    Article  PubMed  CAS  Google Scholar 

  194. Dellagi K, Dupouey P, Brouet JC, et al. Waldenstrom’s macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood. 1983;62(2):280–5.

    PubMed  CAS  Google Scholar 

  195. Bollensen E, Steck AJ, Schachner M. Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology. 1988;38(8):1266–70.

    Article  PubMed  CAS  Google Scholar 

  196. Mata M, Kahn SN, Fink DJ. A direct electron microscopic immunocytochemical study of IgM paraproteinemic neuropathy. Arch Neurol. 1988;45(6):693–7.

    Article  PubMed  CAS  Google Scholar 

  197. Lach B, Rippstein P, Atack D, Afar DE, Gregor A. Immunoelectron microscopic localization of monoclonal IgM antibodies in gammopathy associated with peripheral demyelinative neuropathy. Acta Neuropathol. 1993;85(3):298–307.

    Article  PubMed  CAS  Google Scholar 

  198. Kelly JJ, Adelman LS, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol. 1988;45(12):1355–9.

    Article  PubMed  CAS  Google Scholar 

  199. Donofrio PD, Kelly Jr JJ. AAEE case report #17: peripheral neuropathy in monoclonal gammopathy of undetermined significance. Muscle Nerve. 1989;12(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  200. Smith IS, Kahn SN, Lacey BW, et al. Chronic demyelinating ­neuropathy associated with benign IgM paraproteinaemia. Brain. 1983;106(Pt 1):169–95.

    Article  PubMed  Google Scholar 

  201. Kelly Jr JJ. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve. 1983;6(7):504–9.

    Article  PubMed  Google Scholar 

  202. Sherman WH, Latov N, Hays AP, et al. Monoclonal IgM kappa antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis. Neurology. 1983;33(2):192–201.

    Article  PubMed  CAS  Google Scholar 

  203. Freddo L, Sherman WH, Latov N. Glycosaminoglycan antigens in peripheral nerve. Studies with antibodies from a patient with neuropathy and monoclonal gammopathy. J Neuroimmunol. 1986;12(1):57–64.

    Article  PubMed  CAS  Google Scholar 

  204. Yee WC, Hahn AF, Hearn SA, Rupar AR. Neuropathy in IgM lambda paraproteinemia. Immunoreactivity to neural proteins and chondroitin sulfate. Acta Neuropathol. 1989;78(1):57–64.

    Article  PubMed  CAS  Google Scholar 

  205. Ilyas AA, Li SC, Chou DK, et al. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem. 1988;263(9):4369–73.

    PubMed  CAS  Google Scholar 

  206. Kusunoki S, Shimizu T, Matsumura K, Maemura K, Mannen T. Motor dominant neuropathy and IgM paraproteinemia: the IgM M-protein binds to specific gangliosides. J Neuroimmunol. 1989;21(2–3):177–81.

    Article  PubMed  CAS  Google Scholar 

  207. Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci USA. 1985;82(19): 6697–700.

    Article  PubMed  CAS  Google Scholar 

  208. Kusunoki S, Kohriyama T, Pachner AR, Latov N, Yu RK. Neuropathy and IgM paraproteinemia: differential binding of IgM M-proteins to peripheral nerve glycolipids. Neurology. 1987;37(11):1795–7.

    Article  PubMed  CAS  Google Scholar 

  209. Fredman P. The role of antiglycolipid antibodies in neurological disorders. Ann NY Acad Sci. 1998;845:341–52.

    Article  PubMed  CAS  Google Scholar 

  210. Brouet JC, Danon F, Mihaesco E, Bussel A, Oksenhendler E. Peripheral polyneuropathies associated with monoclonal IgM. Antibody activity of monoclonal IgM and therapeutic implications. Nouv Rev Fr Hematol. 1990;32(5):307–10.

    PubMed  CAS  Google Scholar 

  211. Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. [Review]. Muscle Nerve. 1999;22(7):800–22.

    Google Scholar 

  212. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance [see comment]. Ann Neurol. 1991;30(1):54–61.

    Article  PubMed  CAS  Google Scholar 

  213. Suarez GA, Kelly Jr JJ. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology. 1993;43(7):1304–8.

    Article  PubMed  CAS  Google Scholar 

  214. Chassande B, Leger JM, Younes-Chennoufi AB, et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve. 1998;21(1): 55–62.

    Article  PubMed  CAS  Google Scholar 

  215. Meucci N, Baldini L, Cappellari A, et al. Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann Neurol. 1999;46(1):119–22.

    Article  PubMed  CAS  Google Scholar 

  216. Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand. 1998;97(3):194–200.

    Article  PubMed  CAS  Google Scholar 

  217. Read DJ, Vanhegan RI, Matthews WB. Peripheral neuropathy and benign IgG paraproteinaemia. J Neurol Neurosurg Psychiatry. 1978;41(3):215–9.

    Article  PubMed  CAS  Google Scholar 

  218. Bleasel AF, Hawke SH, Pollard JD, McLeod JG. IgG monoclonal paraproteinaemia and peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1993;56(1):52–7.

    Article  PubMed  CAS  Google Scholar 

  219. Dhib-Jalbut S, Liwnicz BH. Binding of serum IgA of multiple myeloma to normal peripheral nerve. Acta Neurol Scand. 1986;73(4):381–7.

    Article  PubMed  CAS  Google Scholar 

  220. Bailey RO, Ritaccio AL, Bishop MB, Wu AY. Benign monoclonal IgAK gammopathy associated with polyneuropathy and dysautonomia. Acta Neurol Scand. 1986;73(6):574–80.

    Article  PubMed  CAS  Google Scholar 

  221. Simmons Z, Bromberg MB, Feldman EL, Blaivas M. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve. 1993;16(1):77–83.

    Article  PubMed  CAS  Google Scholar 

  222. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology. 1993;43(11):2202–9.

    Article  PubMed  CAS  Google Scholar 

  223. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48(2):321–8.

    Article  PubMed  CAS  Google Scholar 

  224. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain. 1995;118:359.

    Article  PubMed  Google Scholar 

  225. Maisonobe T, Chassande B, Verin M, Jouni M, Leger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry. 1996;61(1):36–42.

    Article  PubMed  CAS  Google Scholar 

  226. Nemni R, Fazio R, Corbo M, Sacchi C, Smirne S, Canal N. Peripheral neuropathy associated with experimental plasma cell neoplasm in the mouse. J Neurol Sci. 1987;77(2–3):321–9.

    Article  PubMed  CAS  Google Scholar 

  227. Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology. 1987;37(2):242–56.

    Article  PubMed  CAS  Google Scholar 

  228. Steck AJ, Murray N, Dellagi K, Brouet JC, Seligmann M. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol. 1987;22(6):764–7.

    Article  PubMed  CAS  Google Scholar 

  229. Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993;33(5):502–6.

    Article  PubMed  CAS  Google Scholar 

  230. Jensen TS, Schroder HD, Jonsson V, et al. IgM monoclonal gammopathy and neuropathy in two siblings. J Neurol Neurosurg Psychiatry. 1988;51(10):1308–15.

    Article  PubMed  CAS  Google Scholar 

  231. Smith T, Sherman WH, Olarte M, Lovelace R. Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study. Acta Med Scand. 1987;223:244.

    Google Scholar 

  232. Frayne J, Stark RJ. Peripheral neuropathy with gammopathy responding to plasmapheresis. Clin Exp Neurol. 1985;21:195–200.

    PubMed  CAS  Google Scholar 

  233. Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann Neurol. 1988;23(4):394–6.

    Article  PubMed  CAS  Google Scholar 

  234. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325(21):1482–6.

    Article  PubMed  CAS  Google Scholar 

  235. Mazzi G, Raineri A, Zucco M, Passadore P, Pomes A, Orazi BM. Plasma-exchange in chronic peripheral neurological disorders. Int J Artif Organs. 1999;22(1):40–6.

    PubMed  CAS  Google Scholar 

  236. Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1995;59(3):243–7.

    Article  PubMed  CAS  Google Scholar 

  237. Notermans NC, Lokhorst HM, Franssen H, et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology. 1996;47(5):1227–33.

    Article  PubMed  CAS  Google Scholar 

  238. Niermeijer JM, Eurelings M, van der Linden M, et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology. 2007;69(1):50–9.

    Article  PubMed  CAS  Google Scholar 

  239. Lunn M. What’s new in paraproteinemic demyelinating neuropathy in 2007-2008? J Peripher Nerv Syst. 2008;13(4):264–6.

    Article  PubMed  Google Scholar 

  240. Sherman W, Latov N, Lange D. Fludarabine for IgM antibody-mediated neuropathies. Ann Neurol. 1994;36:326 (Abstract).

    Google Scholar 

  241. Wilson HC, Lunn MP, Schey S, Hughes RA. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66(5):575–80.

    Article  PubMed  CAS  Google Scholar 

  242. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999;52(8):1701–4.

    Article  PubMed  CAS  Google Scholar 

  243. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 1989;39(3):422–5.

    Article  PubMed  CAS  Google Scholar 

  244. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40(5):792–5.

    Article  PubMed  CAS  Google Scholar 

  245. Younger DS, Rowland LP, Latov N, et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology. 1990;40(4):595–9.

    Article  PubMed  CAS  Google Scholar 

  246. Patten BM. Neuropathy and motor neuron syndromes associated with plasma cell disease. Acta Neurol Scand. 1984;70(1):47–61.

    Article  PubMed  CAS  Google Scholar 

  247. Merlini G, Rutigliano L, Masnaghetti S. Neuromuscular disorders associated with monoclonal immunoglobulins (abstract). Proceedings of International Conference on Multiple Myeloma. Biology, Pathophysiology, Prognosis and Treatment; 1989 June 19–22; Bologna, Italy. p. 215.

    Google Scholar 

  248. Bartoloni C, Scoppetta C, Flamini G, et al. Waldenstrom’s macroglobulinemia and myasthenia gravis. J Clin Lab Immunol. 1981;6(3):275–8.

    PubMed  CAS  Google Scholar 

  249. Galli M, Landi G, Restelli DL, Scarlato G. Myasthenia gravis with a monoclonal gammopathy–report of a case. J Neurol Sci. 1980;45(1):103–8.

    Article  PubMed  CAS  Google Scholar 

  250. Berni I, Costantini A, Di Vano M. Monoclonal gammopathies in Alzheimer disease. Clin Chem. 1993;39(1):166 (Letter to Editor).

    Google Scholar 

  251. McDonald PS, Cora-Bramble D, De Palma L. Monoclonal gammopathy of the immunoglobulin A class in a two-year-old girl with ataxia telangiectasia. Pediatr Dev Pathol. 1998;1(4):319–21.

    Article  PubMed  CAS  Google Scholar 

  252. Sadighi Akha AA, Humphrey RL, Winkelstein JA, Loeb DM, Lederman HM. Oligo-/monoclonal gammopathy and hypergammaglobulinemia in ataxia-telangiectasia. A study of 90 patients. Medicine 1999;78(6):370–81.

    Google Scholar 

  253. Kyle R, Dyck P. Osteosclerotic myeloma (POEMS syndrome). In: Dyck P, Thomas P, Griffin J, editors. Peripheral neuropathy. 3 rd ed. Philadelphia: WB Saunders; 1993. p. 1288.

    Google Scholar 

  254. Nakamoto Y, Imai H, Yasuda T, Wakui H, Miura AB. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant. 1999;14(10):2370–8.

    Article  PubMed  CAS  Google Scholar 

  255. Dupont SA, Dispenzieri A, Mauermann ML, Rabinstein AA, Brown Jr RD. Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology. 2009;73(16):1308–12.

    Article  PubMed  CAS  Google Scholar 

  256. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.

    Article  PubMed  CAS  Google Scholar 

  257. Kelly Jr JJ, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology. 1983;33(2):202–10.

    Article  PubMed  Google Scholar 

  258. Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol. 1983;13(3):543–55.

    PubMed  CAS  Google Scholar 

  259. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore). 1980;59(4):311–22.

    CAS  Google Scholar 

  260. Gherardi RK, Belec L, Soubrier M, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood. 1996;87(4):1458–65.

    PubMed  CAS  Google Scholar 

  261. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21(11):1390–7.

    Article  PubMed  CAS  Google Scholar 

  262. Kuwabara S, Hattori T, Shimoe Y, Kamitsukasa I. Long term ­melphalan-prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry. 1997;63(3):385–7.

    Article  PubMed  CAS  Google Scholar 

  263. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881–7.

    Article  PubMed  CAS  Google Scholar 

  264. James K, Fudenberg H, Epstein WL, Shuster J. Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus). Clin Exp Immunol. 1967;2(2):153–66.

    PubMed  CAS  Google Scholar 

  265. Ohta A, Uitto J, Oikarinen AI. Paraproteinemia in patients with scleredema. Clinical findings and serum effects on skin fibroblasts in vitro. J Am Acad Dermatol. 1987;16(1 Pt 1):96–107.

    Article  PubMed  CAS  Google Scholar 

  266. Rimon D, Lurie M, Storch S, et al. Cardiomyopathy and multiple myeloma. Complications of scleredema adultorum. Arch Intern Med. 1988;148(3):551–3.

    Article  PubMed  CAS  Google Scholar 

  267. McFadden N, Ree K, Soyland E, Larsen TE. Scleredema adultorum associated with a monoclonal gammopathy and generalized hyperpigmentation. Arch Dermatol. 1987;123(5):629–32.

    Article  PubMed  CAS  Google Scholar 

  268. Duguid CM, Powell FC. Pyoderma gangrenosum. Clin Dermatol. 1993;11(1):129–33.

    Article  PubMed  CAS  Google Scholar 

  269. Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum and monoclonal gammopathy. Arch Dermatol. 1983;119(6):468–72.

    Article  PubMed  CAS  Google Scholar 

  270. Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol. 1992;128(1):94–100.

    Article  PubMed  CAS  Google Scholar 

  271. Nestle FO, Hofbauer G, Burg G. Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. Dermatology. 1999;198(4):434–5.

    PubMed  CAS  Google Scholar 

  272. Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol. 2009;145(3):279–84.

    Article  PubMed  Google Scholar 

  273. Puddu P, Cianchini G, Girardelli CR, Colonna L, Gatti S, de Pita O. Schnitzler’s syndrome: report of a new case and a review of the literature [Review]. Clin Exp Rheumatol. 1997;15(1):91–5.

    Google Scholar 

  274. Berard M, Antonucci M, Beaumont JL. Cytotoxic effect of serum on fibroblasts in one case of normolipidemic plane xanthoma and myeloma IgG lambda. Atherosclerosis. 1986;62(2):111–5.

    Article  PubMed  CAS  Google Scholar 

  275. Jones RR, Baughan AS, Cream JJ, Levantine A, Whicher JT. Complement abnormalities in diffuse plane xanthomatosis with paraproteinaemia. Br J Dermatol. 1979;101(6):711–6.

    Article  PubMed  CAS  Google Scholar 

  276. Horne 3rd MK, Merryman P, Cullinane A, Remaley AT. In vitro characterization of a monoclonal IgG(kappa) from a patient with planar xanthomatosis. Eur J Haematol. 2008;80(6):495–502.

    Article  PubMed  CAS  Google Scholar 

  277. Humbert P, Blanc D, Laurent R, Agache P. Monoclonal IgG gammopathy in a case of pustular psoriasis. A ten year follow-up. Blut. 1987;54(1):61–2.

    Article  PubMed  CAS  Google Scholar 

  278. Peltonen L, Nikoskelainen E, Katka K, Tyrkko J. Monoclonal IgG immunoglobulinemia with subsequent myeloma in psoriatic arthritis. Dermatologica. 1984;169(4):207–10.

    Article  PubMed  CAS  Google Scholar 

  279. Ryatt KS, Dodman BA, Cotterill JA. Subcorneal pustular dermatosis and IgA gammopathy. Acta Derm Venereol. 1981;61(6):560–2.

    PubMed  CAS  Google Scholar 

  280. Lutz ME, Daoud MS, McEvoy MT, Gibson LE. Subcorneal ­pustular dermatosis: a clinical study of ten patients. Cutis. 1998;61(4):203–8.

    PubMed  CAS  Google Scholar 

  281. Teixeira M, Lves RA, Seloresi M. Subcorneal pustular dermatosis in association with a monoclonal IgA/k gammopathy: successful treatment with acitretin. Eur J Dermatol. 2006;16(5):588–90.

    PubMed  Google Scholar 

  282. Fernandez de Larrea C, Rovira M, Mascaro JM Jr. et al. Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda monoclonal gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy. Eur J Haematol. 2009;82(2):154–8.

    Google Scholar 

  283. Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol. 1999;40(4):507–35; quiz 36–8.

    Google Scholar 

  284. Venencie PY, Winkelmann RK, Friedman SJ, Kyle RA, Puissant A. Monoclonal gammopathy and mycosis fungoides. Report of four cases and review of the literature. J Am Acad Dermatol. 1984;11 (4 Pt 1):576–9.

    Article  PubMed  CAS  Google Scholar 

  285. Dowd P, Munro D. Erythema elevatum diutinum. J R Soc Med. 1983;76:310.

    PubMed  CAS  Google Scholar 

  286. Kavanagh GM, Colaco CB, Bradfield JW, Archer CB. Erythema elevatum diutinum associated with Wegener’s granulomatosis and IgA paraproteinemia. J Am Acad Dermatol. 1993;28(5 Pt 2):846–9.

    Article  PubMed  CAS  Google Scholar 

  287. Heriot K, Hallquist A, Tomar R. Paraporteinemia in patients with acquired immunodeficiency syndrom (AIDS) or lymphadenopathy syndrome (LAS). Clin Chem. 1985;31:1224–6.

    PubMed  CAS  Google Scholar 

  288. Crapper R, Deam D, Mackay I. Paraproteinemias in homosexual men with HIV infection: lack of association with abnormal clinical or immunologic findings. Am J Clin Pathol. 1987;88:348–51.

    PubMed  CAS  Google Scholar 

  289. Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol. 2007;128(4):596–603.

    Article  PubMed  CAS  Google Scholar 

  290. Lefrere J, Debbia M, Lambin P. Prospective follow-up on gammopathies in HIV-infected individuals. Br J Haematol. 1993;84:151–5.

    Article  PubMed  CAS  Google Scholar 

  291. Turbat-Herrera E, Hancock C, Cabello-Inchausti B, Herrera G. Plasma cell hyperplasia and monoclonal paraproteinemia in human immunodeficiency virus-infected patients. Arch Pathol Lab Med. 1993;117:497.

    PubMed  CAS  Google Scholar 

  292. Renoult E, Bertrand F, Kessler M. Monoclonal gammopathies in HBsAg-positive patients with renal transplants. N Engl J Med. 1988;318:1205 (Letter).

    Google Scholar 

  293. Stanko C, Jeffery J, Rush D. Monoclonal and multiclonal gammopathies after renal transplantation. Transplant Proc. 1989;21:3330–32.

    PubMed  CAS  Google Scholar 

  294. Pollock C, Mahony J, Ibels L, et al. Immunoglobulin abnormalities in renal transplant recipients. Transplantation. 1989;47:952–6.

    Article  PubMed  CAS  Google Scholar 

  295. Radl J, Valentijn R, Haaijman J, Paul L. Monoclonal gammopathies in patients undergoing immunosuppressive treatment after renal transplantation. Clin Immunol Immunopathol. 1985;37:98–102.

    Article  PubMed  CAS  Google Scholar 

  296. Ginevri F, Nocera A, Bonato L, et al. Cytomegalovirus infection is a trigger for monoclonal immunoglobulins in paediatric kidney transplant recipients. Transplant Proc. 1998;30:2079–82.

    Article  PubMed  CAS  Google Scholar 

  297. Ducloux D, Carron P, Racadot E, Rebibou JM, et al. T-cell immune defect and B-cell activation in renal transplant recipients with monoclonal gammopathies. Transplant Int. 1999;12:250–3.

    Article  CAS  Google Scholar 

  298. Passweg J, Bock HA, Tichelli A, Thiel G. ‘Transient multiple myeloma’ after intense immunosuppression in a renal transplant patient. Nephrol Dial Transplant. 1993;8(12):1393–4.

    PubMed  CAS  Google Scholar 

  299. Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal ­gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011;92(5):570–4.

    Google Scholar 

  300. Hammarstrom L, Smith CI. Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation. 1987;43(3):447–9.

    Article  PubMed  CAS  Google Scholar 

  301. Mitus AJ, Stein R, Rappeport JM, et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 1989;74(8):2764–8.

    PubMed  CAS  Google Scholar 

  302. Gerritsen EJ, van Tol MJ, Lankester AC, et al. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation. Blood. 1993;82(11):3493–502.

    PubMed  CAS  Google Scholar 

  303. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood. 1998;91(9):3518–23.

    PubMed  CAS  Google Scholar 

  304. Hebart H, Einsele H, Klein R, et al. CMV infection after allogeneic bone marrow transplantation is associated with the occurrence of various autoantibodies and monoclonal gammopathies. Br J Haematol. 1996;95(1):138–44.

    Article  PubMed  CAS  Google Scholar 

  305. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg. 1996;2(5):375–82.

    Article  PubMed  CAS  Google Scholar 

  306. Pageaux GP, Bonnardet A, Picot MC, et al. Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation. 1998;65(3):397–400.

    Article  PubMed  CAS  Google Scholar 

  307. Pham H, Lemoine A, Salvucci M, et al. Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. Liver Transpl Surg. 1998;4(2):146–51.

    Article  PubMed  CAS  Google Scholar 

  308. Myara I, Quenum G, Storogenko M, Tenenhaus D, Guillemain R, Moatti N. Monoclonal and oligoclonal gammopathies in heart-transplant recipients. Clin Chem. 1991;37(8):1334–7.

    PubMed  CAS  Google Scholar 

  309. Gelfand JA, Boss GR, Conley CL, Reinhart R, Frank MM. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine. 1979;58(4):321–8.

    Article  PubMed  CAS  Google Scholar 

  310. Pascual M, Widmann JJ, Schifferli JA. Recurrent febrile panniculitis and hepatitis in two patients with acquired complement deficiency and paraproteinemia. Am J Med. 1987;83(5):959–62.

    Article  PubMed  CAS  Google Scholar 

  311. Lofdahl CG, Solvell L, Laurell AB, Johansson BR. Systemic capillary leak syndrome with monoclonal IgG and complement alterations. A case report on an episodic syndrome. Acta Med Scand. 1979;206(5):405–12.

    PubMed  CAS  Google Scholar 

  312. Pascual M, Mach-Pascual S, Schifferli JA. Paraproteins and complement depletion: pathogenesis and clinical syndromes. Semin Hematol. 1997;34 Suppl 1:40–8.

    PubMed  CAS  Google Scholar 

  313. Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med. 1992;92(5):523–6.

    Article  PubMed  CAS  Google Scholar 

  314. Hendrick AM, Mitchison HC, Bird AG, James OF. Paraproteins in primary biliary cirrhosis. Q J Med. 1986;60(231):681–4.

    PubMed  CAS  Google Scholar 

  315. Mussini C, Ghini M, Mascia MT, et al. HCV and monoclonal gammopathies. Clin Exp Rheumatol. 1995;13 Suppl 13:S45–9.

    PubMed  Google Scholar 

  316. Mangia A, Clemente R, Musto P, et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia. 1996;10(7):1209–13.

    PubMed  CAS  Google Scholar 

  317. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med. 1998;129(4):294–8.

    PubMed  CAS  Google Scholar 

  318. Dosa S, Cairns SA, Mallick NP, Lawler W, Williams G. Relapsing Henoch-Schonlein syndrome with renal involvement in a patient with an IgA monoclonal gammopathy. A study of the results of immunosuppressant and cytotoxic therapy. Nephron. 1980;26(3):145–8.

    Article  PubMed  CAS  Google Scholar 

  319. Fauchier C, Youinou P, Le Goff P, Garre M, Le Moigne P, Le Menn G. Monocional immunoglobulins associated with bacterial endocarditis. Two case reports (author’s transl). Sem Hop. 1979;55(41–42):1903–4.

    PubMed  CAS  Google Scholar 

  320. Groussin P, Fine JM, Leroux E. Thyroidite d’Hashimoto et gammapathie monoclonale: Deux observations. Ann Endocrinol (Paris).1979;40:413–6.

    Google Scholar 

  321. Matsubayashi S, Tamai H, Nagai K. Monoclonal gammopathy in Hashimoto’s thyroiditis and malignant lymphoma of the thyroid. J Clin Endocrinol Metab. 1986;63:1136–9.

    Article  PubMed  CAS  Google Scholar 

  322. Norenberg D, Bigley D, Virat R, Liang G. Corynebacterium pyogenes septic arthritis with plasma cell synhovial infiltrate and monoclonal gammopathy. Arch Intern Med. 1978;138:810–1.

    Article  PubMed  CAS  Google Scholar 

  323. Friedenburg W, West M, Miech D, Mazza J. Atypical purpura fulminans with benign monoclonal gammopathy. Arch Dermatol. 1978;114:578–80.

    Article  Google Scholar 

  324. Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis. A possible dysproteinemic and genetically determined disease. Am J Med. 1965;39:411–21.

    Article  PubMed  CAS  Google Scholar 

  325. Mork JN, Johnson JR, Zinneman HH, Bjorgen J. Pulmonary alveolar proteinosis associated with IgG monoclonal gammopathy. Arch Intern Med. 1968;121(3):278–83.

    Article  PubMed  CAS  Google Scholar 

  326. Nomura S, Kanoh T. Association of idiopathic pulmonary haemosiderosis with IgA monoclonal gammopathy. Thorax. 1987;42(9):696–7.

    Article  PubMed  CAS  Google Scholar 

  327. Sharma AM, Fried J, Sharma OP. Monoclonal gammopathy of undetermined significance in sarcoidosis. Two case reports. Sarcoidosis. 1992;9(1):70–2.

    PubMed  CAS  Google Scholar 

  328. Soppi E, Eskola J, Roytta M, Veromaa T, Panelius M, Lehtonen A. Thymoma with immunodeficiency (Good’s syndrome) associated with myasthenia gravis and benign IgG gammopathy. Arch Intern Med. 1985;145(9):1704–7.

    Article  PubMed  CAS  Google Scholar 

  329. Schafer AI, Miller JB, Lester EP, Bowers TK, Jacob HS. Monoclonal gammopathy in hereditary spherocytosis: a possible pathogenetic relation. Ann Intern Med. 1978;88(1):45–6.

    PubMed  CAS  Google Scholar 

  330. Munteanu G. L’heredodystrophie maculaire de Doyne et la gammopathie monoclonale benigne. Correlations genetiques et pathogeniques. J Fr Ophtalmol. 1980;3(12):753–8.

    PubMed  CAS  Google Scholar 

  331. Nagler A, Ben-Arieh Y, Brenner B, Tatarsky I, Pollack S. Eosinophilic fibrohistiocytic lesion of bone marrow associated with monoclonal gammopathy and osteolytic lesions. Am J Hematol. 1986;23(3):277–81.

    Article  PubMed  CAS  Google Scholar 

  332. Ormerod LD, Collin HB, Dohlman CH, Craft JL, Desforges JF, Albert DM. Paraproteinemic crystalline keratopathy. Ophthalmology. 1988;95(2):202–12.

    PubMed  CAS  Google Scholar 

  333. Bourne WM, Kyle RA, Brubaker RF, Greipp PR. Incidence of corneal crystals in the monoclonal gammopathies. Am J Ophthalmol. 1989;107(2):192–3.

    PubMed  CAS  Google Scholar 

  334. Kato T, Nakayasu K, Omata Y, Watanabe Y, Kanai A. Corneal deposits as an alerting sign of monoclonal gammopathy: a case report. Cornea. 1999;18(6):734–8.

    Article  PubMed  CAS  Google Scholar 

  335. Hutchinson K, Dal Pra M, Apel A. Immunoglobulin G crystalline keratopathy associated with monoclonal gammopathy. Aust NZ J Ophthalmol. 1998;26(2):177–9.

    Article  CAS  Google Scholar 

  336. Zadak Z, Tichy M. Hyperlipidemia and monoclonal gammapathy. Neoplasma. 1987;34(2):169–72.

    PubMed  CAS  Google Scholar 

  337. Meyrier A, Simon P, Mignon F, Striker L, Ramee MP. Rapidly progressive (‘crescentic’) glomerulonephritis and monoclonal gammapathies. Nephron. 1984;38(3):156–62.

    Article  PubMed  CAS  Google Scholar 

  338. Kebler R, Kithier K, McDonald FD, Cadnapaphornchai P. Rapidly progressive glomerulonephritis and monoclonal gammopathy. Am J Med. 1985;78(1):133–8.

    Article  PubMed  CAS  Google Scholar 

  339. Cadnapaphornchai P, Sillix D. Recurrence of monoclonal gammopathy-related glomerulonephritis in renal allograft. Clin Nephrol. 1989;31(3):156–9.

    PubMed  CAS  Google Scholar 

  340. Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis. 2005;46(2):278–82.

    Article  PubMed  Google Scholar 

  341. Chen HP, Carroll JA. Monoclonal gammopathy in carcinoma of the colon. Am J Clin Pathol. 1980;73(4):607–10.

    PubMed  CAS  Google Scholar 

  342. Dighiero G, Guilbert B, Fermand JP, Lymberi P, Danon F, Avrameas S. Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood. 1983;62(2):264–70.

    PubMed  CAS  Google Scholar 

  343. Bäck H, Nilsson G, Hansson GK, Rodjer S, Tarkowski A. M-component with reactivity against actin associated with thrombotic thrombocytopenic purpura. Am J Med. 1991;91(4):429–33.

    Article  PubMed  Google Scholar 

  344. Csako G, Costello R, Shamim EA, et al. Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. Arthritis Res Ther. 2007;9:R95.

    Article  PubMed  CAS  Google Scholar 

  345. Shimm DS, Cohen HJ. Transient monoclonal immunoglobulin G with anti-dextran activity. Acta Haematol. 1978;59(2):99–103.

    Article  PubMed  CAS  Google Scholar 

  346. Kalliomaki JL, Granfors K, Toivanen A. An immunoglobulin G myeloma with antistreptolysin activity and a lifelong history of cutaneous streptococcal infection. Clin Immunol Immunopathol. 1978;9(1):22–7.

    Article  PubMed  CAS  Google Scholar 

  347. Intrator L, Andre C, Chenal C, Sultan C. A monoclonal macroglobulin with antinuclear activity. J Clin Pathol. 1979;32(5):450–4.

    Article  PubMed  CAS  Google Scholar 

  348. Ruiz-Palomo F, Revilla Y, Gonzales Porque P, Serrano Rios M. Two IgM paraproteins bearing cryoglobulin and anti-smooth muscle activities in a patient with Waldenstrom’s macroglobulinaemia. J Intern Med. 1991;229(1):93–6.

    Article  PubMed  CAS  Google Scholar 

  349. Farhangi M, Osserman EF. Myeloma with xanthoderma due to an IgG lambdamonoclonal anti-flavin antibody. N Engl J Med. 1976;294(4):177–83.

    Article  PubMed  CAS  Google Scholar 

  350. Merlini G, Bruening R, Kyle RA, Osserman EF. The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization. Mol Immunol. 1990;27(5):385–94.

    Article  PubMed  CAS  Google Scholar 

  351. Bovill EG, Ershler WB, Golden EA, Tindle BH, Edson JR. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol. 1986;85(1):115–23.

    PubMed  CAS  Google Scholar 

  352. Mohri H, Noguchi T, Kodama F, Itoh A, Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol. 1987;87(5):663–8.

    PubMed  CAS  Google Scholar 

  353. Zouali M, Fine JM, Eyquem A. A human monoclonal IgG1 with anti-idiotypic activity against anti-human thyroglobulin autoantibody. J Immunol. 1984;133(1):190–4.

    PubMed  CAS  Google Scholar 

  354. Sluiter WJ, Marrink J, Houwen B. Monoclonal gammopathy with an insulin binding IgG(K) M-component, associated with severe hypoglycaemia. Br J Haematol. 1986;62(4):679–87.

    Article  PubMed  CAS  Google Scholar 

  355. Fermand JP, Danon F, Brouet JC. Characterization of a human monoclonal IgM with antibody activity to dsDNA. Clin Exp Immunol. 1985;59(2):467–74.

    PubMed  CAS  Google Scholar 

  356. Kilgore LL, Patterson BW, Parenti DM, Fisher WR. Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest. 1985;76(1):225–32.

    Article  PubMed  CAS  Google Scholar 

  357. Trimarchi F, Benvenga S, Fenzi G, Mariotti S, Consolo F. Immunoglobulin binding of thyroid hormones in a case of Waldenstrom’s macroglobulinemia. J Clin Endocrinol Metab. 1982;54(5):1045–50.

    Article  PubMed  CAS  Google Scholar 

  358. Wisloff F, Michaelsen TE, Godal HC. Monoclonal IgM with lupus anticoagulant activity in a case of Waldenstrom’s macroglobulinaemia. Eur J Haematol. 1987;38(5):456–60.

    Article  PubMed  CAS  Google Scholar 

  359. Backer ET, Harff GA, Beyer C. A patient with an IgG paraprotein and complexes of lactate dehydrogenase and IgG in the serum. Clin Chem. 1987;33(10):1937–8.

    PubMed  CAS  Google Scholar 

  360. Ng VL, Hwang KM, Reyes GR, et al. High titer anti-HIV antibody reactivity associated with a paraprotein spike in a homosexual male with AIDS related complex. Blood. 1988;71(5):1397–401.

    PubMed  CAS  Google Scholar 

  361. Del Carpio J, Espinoza LR, Lauter S, Osterland CK. Transient monoclonal proteins in drug hypersensitivity reactions. Am J Med. 1979;66(6):1051–6.

    Article  PubMed  Google Scholar 

  362. DiMinno G, Coraggio F, Cerbone AM, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest. 1986;77(1):157–64.

    Article  PubMed  CAS  Google Scholar 

  363. Hoyt RH, Durie BG. Pseudothrombocytopenia induced by a monoclonal IgM kappa platelet agglutinin. Am J Hematol. 1989;31(1):50–2.

    Article  PubMed  CAS  Google Scholar 

  364. Merlini G, Fitzpatrick LA, Siris ES, et al. A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol. 1984;4(3):185–96.

    Article  PubMed  CAS  Google Scholar 

  365. Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin Proc. 1982;57(9):572–5.

    PubMed  CAS  Google Scholar 

  366. Baker BL, Hultquist DE. A copper-binding immunoglobulin from a myeloma patient. Purification, identification, and physical characterization. J Biol Chem. 1978;253(4):1195–200.

    PubMed  CAS  Google Scholar 

  367. Martin NF, Kincaid MC, Stark WJ, et al. Ocular copper deposition associated with pulmonary carcinoma. IgG monoclonal gammopathy and hypercupremia. A clinicopathologic correlation. Ophthalmology. 1983;90(1):110–6.

    PubMed  CAS  Google Scholar 

  368. Westerhausen M, Meuret G. Transferrin-immune complex disease. Acta Haematol. 1977;57(2):96–101.

    Article  PubMed  CAS  Google Scholar 

  369. Numata Y, Tanioka F, Yoshida K, et al. Ascertainment of IgA1 (kappa)-transferrin complex in a case of multiple myeloma associated with hypersiderinemia. Jpn J Med. 1991;30(6):498–503.

    Article  PubMed  CAS  Google Scholar 

  370. Alyanakian MA, Taes Y, Bensaid M, et al. Monoclonal immunoglobulin with antitransferrin activity: a rare cause of hypersideremia with increased transferrin saturation. Blood. 2007;109(1):359–61.

    Article  PubMed  CAS  Google Scholar 

  371. Hilgard P, Linder KH, Wetter O. Monoclonal cryoglobulin of IgG (lambda) type interacting with transferrin. Blut. 1981;43(4):217–25.

    Article  PubMed  CAS  Google Scholar 

  372. Pettersson T, Hortling L, Teppo AM, Totterman KJ, Fyhrquist F. Phosphate binding by a myeloma protein. Acta Med Scand. 1987;222(1):89–91.

    Article  PubMed  CAS  Google Scholar 

  373. Pierce T, Joshi H, Patel S. Apparent affinity of multiple myeloma (MM) paraprotein for serum phosphate. Blood. 1988;72:253a (abstract).

    Google Scholar 

  374. Halsall DJ, Mangi M, Soos M, et al. Hypoglycemia due to an insulin binding antibody in a patient with an IgA-kappa myeloma. J Clin Endocrinol Metab. 2007;92(6):2013–6.

    Article  PubMed  CAS  Google Scholar 

  375. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–9.

    Article  PubMed  CAS  Google Scholar 

  376. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol. 2010;28(4):690–7.

    Article  PubMed  CAS  Google Scholar 

  377. Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res. 2005;11(5):1786–90.

    Article  PubMed  CAS  Google Scholar 

  378. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759–64.

    Article  PubMed  CAS  Google Scholar 

  379. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23(21):4662–8.

    Article  PubMed  Google Scholar 

  380. Sakashita C, Saito T, Kurosu T, et al. Two M-components in a single cell lineage in a patient with a dual isotype secretory B-cell tumour. Br J Haematol. 1998;102(3):791–4.

    Article  PubMed  CAS  Google Scholar 

  381. Pizzolato M, Bragantini G, Bresciani P, et al. IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. Br J Haematol. 1998;102(2):503–8.

    Article  PubMed  CAS  Google Scholar 

  382. Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med. 1981;71(6):999–1008.

    Article  PubMed  CAS  Google Scholar 

  383. Nilsson T, Norberg B, Rudolphi O, Jacobsson L. Double gammopathies: incidence and clinical course of 20 patients. Scand J Haematol. 1986;36(1):103–6.

    Article  PubMed  CAS  Google Scholar 

  384. Riddell S, Traczyk Z, Paraskevas F, Israels LG. The double gammopathies. Clinical and immunological studies. Medicine (Baltimore). 1986;65(3):135–42.

    CAS  Google Scholar 

  385. Lucivero G, Miglietta A, Dell’Osso A, Theodossiu G, Bonomo L. Double (IgA kappa  +  IgG kappa) paraproteinaemia in a single patient: immunofluorescence evidence for a common plasma cell clone ‘frozen’ at the switch phase. Acta Haematol. 1986;75(4):224–8.

    Article  PubMed  CAS  Google Scholar 

  386. Ilyas AA, Willison HJ, Dalakas MC, Whitaker JN, Quarles RH. Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy. J Neurochem. 1988;51(3):851–8.

    Article  PubMed  CAS  Google Scholar 

  387. Ray RA, Schotters SB. Triclonal gammopathy in a patient with AIDS. Clin Chem. 1986;32(10):2000 (Letter).

    Google Scholar 

  388. Berg AR, Weisenburger DD, Linder J, Armitage JO. Lymphoplasmacytic lymphoma. Report of a case with three monoclonal proteins derived from a single neoplastic clone. Cancer. 1986;57(9):1794–7.

    Article  PubMed  CAS  Google Scholar 

  389. Murata T, Fujita H, Harano H, et al. Triclonal gammopathy (IgA kappa, IgG kappa, and IgM kappa) in a patient with plasmacytoid lymphoma derived from a monoclonal origin. Am J Hematol. 1993;42(2):212–6.

    Article  PubMed  CAS  Google Scholar 

  390. Grosbois B, Jego P, de Rosa H, et al. [Triclonal gammopathy and malignant immunoproliferative syndrome]. (French). Revue de Medecine Interne. 1997;18(6):470–3.

    Article  PubMed  CAS  Google Scholar 

  391. Kyle RA, Greipp PR. “Idiopathic” Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med. 1982;306(10):564–7.

    Article  PubMed  CAS  Google Scholar 

  392. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans. 1850;33:211–32.

    PubMed  CAS  Google Scholar 

  393. O’Connor ML, Rice DT, Buss DH, Muss HB. Immunoglobulin D benign monoclonal gammopathy. A case report. Cancer. 1991;68(3):611–6.

    Article  PubMed  Google Scholar 

  394. Hobbs JR, Corbett AA. Younger age of presentation and extraosseous tumour in IgD myelomatosis. Br Med J. 1969;1(5641):412–4.

    Article  PubMed  CAS  Google Scholar 

  395. Hansen NE, Karle H, Olsen JH. Trends in the incidence of multiple myeloma in Denmark 1943-1982: a study of 5500 patients. Eur J Haematol. 1989;42(1):72–6.

    Article  PubMed  CAS  Google Scholar 

  396. Blade J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol. 1994;88(2):395–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by Research grants CA-62242 and CA-107476 from the National Cancer Institute.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Robert A. Kyle M.D. & S. Vincent Rajkumar M.D.

Authors
  1. Robert A. Kyle M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Vincent Rajkumar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Vincent Rajkumar M.D. .

Editor information

Editors and Affiliations

  1. Beth Israel Hospital, Cancer Center, St. Lukes-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Peter H. Wiernik

  2. , Department of Hematology, Imperial College of London, Du Cane Road 150, London, W12 0NN, United Kingdom

    John M. Goldman

  3. Continuum Cancer Centers, Department of Medicine, St. Luke's-Roosevelt Hospital Center, 10th Avenue 1000, New York, 10019, New York, USA

    Janice P. Dutcher

  4. , Division of Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Robert A. Kyle

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kyle, R.A., Rajkumar, S.V. (2013). Monoclonal Gammopathy of Undetermined Significance. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3764-2_38

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3763-5

  • Online ISBN: 978-1-4614-3764-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation